Drug intelligence / Profile preview

amikacin + gentamicin

Development stage: Unknown
Lead developer: Huazhong Pharmaceutical
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination of two aminoglycoside antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination is used for serious bacterial infections, particularly those caused by gram-negative bacteria, though it carries increased risk of toxicity compared to either agent alone.

Targets

H69 (Bacterial 50S ribosomal subunit helix 69)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on amikacin + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amikacin + gentamicin.

Explore the full profile